Remeditex was formed to invest in high quality, innovative, early stage projects that are judged to have commercialization potential.
Business Model:
Revenue: $7.3M
Employees: 2-10
Address: 2101 Cedar Springs Rd
City: Dallas
State: TX
Zip: 75201
Country: US
Remeditex was formed to invest in high quality, innovative, early stage projects that are judged to have commercialization potential. The goal is to help investigators establish the commercial viability of their research making it attractive to traditional investors.
Contact Phone:
+12145062662
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
2/2015 | Viridian Therapeutics | Series B | 0 |
11/2015 | Viridian Therapeutics | Series C | 0 |
3/2012 | Bellicum Pharmaceuticals | Series B | 20M |
9/2017 | Rodin Therapeutics | Series C | 0 |
4/2012 | Viridian Therapeutics | Series B | 20M |
7/2011 | Peloton Therapeutics | Series A | 18M |
6/2019 | Soliton | Post-IPO Equity | 0 |
5/2015 | VYNE Therapeutics | Series A | 14.3M |
2/2012 | Apollo Endosurgery | Series B | 0 |
6/2014 | Viridian Therapeutics | Series B | 7M |
1/2014 | Bellicum Pharmaceuticals | Series B | 14.7M |
7/2017 | VYNE Therapeutics | Series C | 50.5M |
3/2009 | BiOptix Diagnostics | Series A | 3M |
11/2015 | VYNE Therapeutics | Series B | 45M |
12/2015 | Navitor Pharmaceuticals | Series B | 33M |
9/2012 | Bi02 Medical | Series C | 0 |
9/2016 | Peloton Therapeutics | Series D | 0 |
6/2019 | Soliton | Post-IPO Equity | 0 |
9/2017 | Rodin Therapeutics | Series C | 0 |
7/2017 | VYNE Therapeutics | Series C | 0 |
9/2016 | Peloton Therapeutics | Series D | 0 |
12/2015 | Navitor Pharmaceuticals | Series B | 0 |
11/2015 | Viridian Therapeutics | Series C | 0 |
11/2015 | VYNE Therapeutics | Series B | 0 |
5/2015 | VYNE Therapeutics | Series A | 0 |
2/2015 | Viridian Therapeutics | Series B | 0 |
6/2014 | Viridian Therapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|